The approach of using an anti-CD47 and anti-PDL1 antibody pair conjugated to the surface of a nanoparticle encasing a PI3K-AKT-mTOR inhibitor, proved to be more efficacious in reducing tumor burden in a non-small cell lung cancer immunocompetent mouse model, compared with current approaches using a PDL1 inhibitor [420]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.